positive, HER2-negative (HR+/HER2-) breast cancer (BC):-Breast01 trial (2023 ESMO-LBA11).[6] Chmid P
:. Poster 198P. 2023 ESMO BC.[5]Sara M. Tolaney, Aditya Bardia, Frederik Marm’e et al. Final overall
Burn DJ, Fitts MS, Gasser T, Klein C, de Tijssen MAJ, Lang AE, Lim SY, Litvan I, Meissner WG